68Ga-FAPi-46 PET/CT Scan in Imaging Patients With Sarcoma
Running, not enrolling · Early Phase 1
Conditions studied: Metastatic Sarcoma, Recurrent Sarcoma, Sarcoma
In brief
This early phase I trial studies an imaging technique called 68Ga-FAPi-46 PET/CT to determine where and to which degree the FAPI tracer (68Ga-FAPi-46) accumulates in normal and cancer tissues in patients with sarcoma. PET is an established imaging technique that utilizes small amounts of radioactivity attached to very minimal amounts of tracer, in the case of this research, 68Ga-FAPi. Because some cancers take up 68Ga-FAPi it can be seen with PET. CT utilizes x-rays that traverse body from the outside. CT images provide an exact outline of organs and potential inflammatory tissue where it occurs in patient's body.
Key facts
- Study ID
- NCT04457258
- Run by
- Jonsson Comprehensive Cancer Center
- People needed
- 18
- Starts
- 2020-09-08
- Expected to finish
- 2027-12-02
- Last updated by the study team
- 2026-07-17
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Patients who are scheduled to undergo surgical excision or biopsy of a suspected sarcoma primary, or a suspected recurrent or metastatic lesion.
- Patients who are ≥ 18 years old at the time of the radiotracer administration.
- Patients who can provide written informed consent.
- Patients who are able to remain still for duration of imaging procedures (up to one hour for each).
You may not qualify if…
- Patient is pregnant or nursing.
- Patients with any new cancer therapy between the baseline 18F-FDG PET/CT and the investigational FAPI PET/CT
- Patient has underlying disease which, based on the judgment of the investigator, might interfere with the collection of high quality data.
Where it is running
- UCLA / Jonsson Comprehensive Cancer Center — Los Angeles, California, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.